Skip to main content
. 2011 Oct 13;16(6):430–443. doi: 10.3109/13625187.2011.614029

Figure 3.

Figure 3

(A) Incidences (%) and (B) duration (median number of days) of breakthrough bleeding-spotting for N0MAC/E2 (grey bars) and DRSP/EE (black bars). The incidences were compared statistically between the treatment groups. *p < 0.05 vs. DRSP/EE. NOMAC, nomegestrol acetate; E2, oestradiol; EE, ethinylestradiol; DRSP drospirenone.